---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Administration"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Administration. Topics: Oral soft capsule, Self-administration after investigator-confirmed attack qualification in the phase 3 trial, Attacks eligible for treatment in the phase 3 trial, Timing of home treatment in the phase 2 trial, and 3 further topics. 7 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/administration"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Administration

<a id="heading-2.1.2.10.2"></a>

## 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

### Oral soft capsule

> “Deucrictibant Soft Capsules for Oral Use”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-2.1.2.10.2-2"></a>

### Self-administration after investigator-confirmed attack qualification in the phase 3 trial

> “Each attack was then assessed and qualified by the investigator during a telephone call or other live communication. Following investigator-confirmed qualification and before administration of the study drug, participants completed their pre-treatment assessments, including PGI-S and AMRA ratings, using the ePRO instruments on the electronic device. During the qualification call with the investigator or immediately following, patients then self-administered the study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.2-3"></a>

### Attacks eligible for treatment in the phase 3 trial

> “Qualifying attacks were defined as either non-laryngeal attacks, with at least one symptom item score of 20 or more on the angioedema symptom rating scale (AMRA) assessment, which measures skin swelling, skin pain, and abdominal pain, as described below, or non-severe laryngeal attacks without breathing difficulties or stridor.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.2-4"></a>

### Timing of home treatment in the phase 2 trial

> “In Part 2, patients were instructed to self-administer deucrictibant at home in the assigned treatment sequence to treat three investigator-confirmed qualifying attacks within 3 h after at least one symptom (skin pain, skin swelling, or abdominal pain) reached a visual analog scale (VAS) individual score of at least 30 out of 100 and within 6 h from symptom onset.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.1.2.10.2-5"></a>

### Packaging in the phase 3 trial: one capsule per blister wallet

> “The study drug was packaged in aluminium–aluminium blisters. Each blister was sealed into a wallet, labelled with a booklet label, and rendered tamper evident. Each wallet contained one single capsule (either deucrictibant or placebo).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.2-6"></a>

### Capsule ingestion during laryngeal and abdominal attacks

> “No issues with capsule ingestion, such as difficulty swallowing, were reported, including for laryngeal attacks, and no reports of vomiting following study drug administration were reported in participants with abdominal symptoms.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.2-7"></a>

### Administration with respect to food

> “No significant impact of food intake on achievement of therapeutic levels”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
